WeightWatchers Files for Chapter 11 Bankruptcy Amid Competition from Ozempic, Mounjaro

31 posts • Grok (2)

Updated May 10, 2025, 01:03 AM

WeightWatchers, a leading weight management company, has filed for Chapter 11 bankruptcy protection in the U.S. on May 6, 2025, amid significant debt and fierce competition from weight-loss drugs like Ozempic and Mounjaro. The company, which began with one housewife in New York and grew into a global enterprise, announced the filing to restructure its financial situation by annulling $1.15 billion of its debt. The rise in popularity of these injectable medications, which are also used for diabetes treatment, has impacted traditional weight-loss programs. WeightWatchers' stock plummeted over 40% on Wall Street following the announcement, with shares dropping to $0.42 from a peak of $101 in 2018. Despite the filing, WeightWatchers will continue to operate normally, ensuring no disruption to its members' services. The CEO emphasized the company's commitment to remain in the market and adapt to the changing landscape of weight management.

More breaking stories on DeepNewz — updated live.

#WeightWatchers #Ozempic #Mounjaro #New York #Wall Street

Associated Financial Markets

More financial news and market updates→

Related Prediction Markets

Trump confirmed taking Ozempic before July?

New excavation beneath Giza pyramids announced before July?

Another Earthquake 7.0 or above in May?

•

View market suggestions→

Sources

telegraph.co.uk(3)thefp.com(3)newscientist.com(2)insideprecisionmedicine.com

Crémieux

@cremieuxrecueil

Here are some recently-voiced, but quickly debunked or otherwise unserious concerns about GLP-1RAs. Usually false claims travel further than debunkings, so I hope writing this down helps at least a few people realize they were misled. https://t.co/xP2s9OS2Ei

Inside Precision Medicine

@Inside_PM

A Genetic Risk Score for GLP-1 Agonist-Related Nausea A team led by researchers at @MayoClinic developed a new risk score that predicts which patients may experience GI side effects from GLP-1 agonists like #Wegovy and #Zepbound. #GLP1 #WeightLossDrug https://t.co/U3BFcb1X5J